Regulus Therapeutics Inc - Volume dana dhuwit perusahaan RGLS

Lambang korporat lan logo Regulus Therapeutics Inc. (RGLS)

The lack of pricing power during the RNA drug testing phase is confirmed by the trend in cash on hand, where 0.06 reflects the latest metric value. However, fixed R&D costs and future FDA patents will provide powerful operating leverage. The secure US perimeter and the humanitarian status of medicine fully shield Regulus Therapeutics (RGLS) developments from geopolitical risks.

Regulus - Volume dana dhuwit perusahaan RGLS (periode 04.07.2022 - 05.07.2025)

Rincian analitis lan laporan data perusahaan Regulus Therapeutics Inc. (RGLS)

- nilai saham lan prakiraan konsensus rega:
Analisis fundamental perusahaan:RGLS regulusrx.com
Produk merek regulusrx.com

Defensive assets are selected based on the criterion of high operational resilience. Regulus Therapeutics (RGLS) meets this standard by funding complex developments in RNA interference and DNA therapy. This metric captures the absolute volume of liquid assets on the issuer's accounts, excluding temporary reporting gaps. By analyzing the cash reserve trend, an investor assesses the company's ability to maintain research autonomy. Excess capital minimizes default risk but may reduce overall portfolio returns.

Pesaing utama

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|PRME (Prime Medicine Inc) - Volume dana dhuwit perusahaan|Taysha Gene Therapies (TSHA) - Aset likuid perusahaan|Dhuwit awis perusahaan QURE (uniqure.com)|Gunggung dana dhuwit perusahaan MGTX|Volume dana dhuwit perusahaan RGNX (regenxbio.com)|SLDB: Dhuwit awis lan setara dhuwit awis perusahaan|ocugen.com - Volume dana dhuwit perusahaan|PACB - Volume dana dhuwit perusahaan|BNTC: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan DSGN|Dana dhuwit perusahaan Rocket Pharmaceuticals|Dhuwit awis perusahaan 4DMT (FDMT)|Volume dana dhuwit perusahaan LXEO|Aset likuid perusahaan Korro Bio Inc.|Volume dana dhuwit perusahaan EDIT (Editas Medicine Inc)|SLN: Dhuwit awis lan setara dhuwit awis perusahaan|PRQR - Dana dhuwit perusahaan|Aset likuid perusahaan codexis.com CDXS|SGMO: Volume dana dhuwit perusahaan|Nautilus Biotechnology (NAUT) - Volume dana dhuwit perusahaan|Dana dhuwit perusahaan Metagenomi, Inc|precisionbiosciences.com (DTIL) - Aset likuid perusahaan|Dana dhuwit perusahaan Generation Bio Co. (GBIO)|Aset likuid perusahaan Boundless Bio, Inc.|Dana dhuwit perusahaan Exicure, Inc. XCUR|IMNN: Dhuwit awis lan setara dhuwit awis perusahaan|PHIO - Dana dhuwit perusahaan|Aset likuid perusahaan Mustang Bio MBIO|RNAZ: Volume dana dhuwit perusahaan|Posisi dhuwit perusahaan Bionano Genomics Inc. BNGO|APDN (Applied DNA Corp) - Volume dana dhuwit perusahaan|bluebirdbio.com (BLUE) - Aset likuid perusahaan|Volume dana dhuwit perusahaan IPA|Volume dana dhuwit perusahaan Omega (OMGA)|Dana dhuwit perusahaan Singular Genomics Systems Inc OMIC|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan